DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that pioneers the application of biodiversity from the natural environment to tackle the global challenge of antimicrobial resistance and the need for next-generation active ingredients for Health, announces the signing of an evaluation and technology development license with DSM, a global science-based company in Nutrition, Health and Sustainable Living.
Under the agreement, DSM will evaluate the potential of a microbial strain from DEINOVE as a feed additive; selected and characterized during the Color-2B program. The evaluation and technology development program is undertaken and supervised by DSM. For the exclusive purpose of the performance of the collaboration activities, DSM is granted a temporary exclusive license to use DEINOVE’s proprietary strain, as well as the background intellectual property related to the strain and required for the collaboration activities. In consideration of these provisions, DEINOVE will receive a upfront and milestone payments during program execution (undisclosed amount). Upon DSM’s decision that the collaboration activities are successful, DEINOVE and DSM will pursue negotiations for a commercial license agreement.
"This collaboration with a major player in the field of animal nutrition is totally in line with our R&D partnering strategy in the non-therapeutic activities and underlines the quality of the work that has been done in the Color-2B program” commented Alexis Rideau, Deputy CEO of DEINOVE. "We hope that the evaluation and technology development program will lead to the launch of a new active ingredient that has been brought to light by DEINOVE from its proprietary strain collection.”